Interaction Checker

Interacciones de Temozolomida

Temozolomida (Temodar) tiene 32 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 9; moderadas: 23; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (9)

  • Clotrimazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • DacarbazinaGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • Econazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • Fluconazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • Itraconazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • Ketoconazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • Miconazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • Posaconazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

  • Voriconazolantifúngico azólicoGrave

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (etiqueta de Temozolomida, Contraindicaciones)

Interacciones moderadas (23)

  • Azelastina y fluticasonaantihistamínicoModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • BetametasonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • BudesonidacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • CiclesonidacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • ClobetasolcorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • DeflazacortcorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • FluticasonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • HalobetasolcorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • HidrocortisonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • PrednisolonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • TriamcinolonacorticosteroideModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

Compruebe Temozolomida frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.